Emerging Markets Earnings Roundup: AstraZeneca And Roche (Part 4)
This article was originally published in PharmAsia News
Executive Summary
Although AstraZeneca achieved 17% growth in China for 2012, there is room for improvement, CEO Pascal Soriot told investors. Meanwhile, Soriot’s old company Roche seems to be discussing emerging markets less on its quarterly calls since he left, but nevertheless ramps up sales for key products Avastin and Herceptin.